Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.
Ali BazarbachiChristoph SchmidMyriam LabopinDietrich BeelenIgor Wolfgang BlauVictoria PotterRiitta NiittyvuopioGerard SociéDidier BlaiseJaime Sanz CaballerFabio CiceriIman Abou DalleAlexandros SpirydonidisGesine BugJordi EsteveBipin P SavaniArnon NaglerMohamad MohtyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Outcome after posttransplant relapse among younger patients has improved significantly in recent years, likely reflecting, among other factors, the efficacy of posttransplant salvage including second allo-HCT.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- multiple sclerosis
- prognostic factors
- bone marrow
- peritoneal dialysis
- stem cells
- acute myeloid leukemia
- stem cell transplantation
- rheumatoid arthritis
- mesenchymal stem cells
- acute lymphoblastic leukemia
- cell proliferation
- cell therapy
- hematopoietic stem cell